In a bid to find possible treatment for preventing onset of memory related diseases, drugmaker Novartis is going to test two experimental Alzheimer’s drugs on people with higher genetic risk of developing such memory-robbing disease.
According to the company, the test aims at gauging whether the treatments can prevent or delay symptoms of those memory-robbing diseases.
The Swiss drugmaker will team up with the Banner Alzheimer’s Institute to study two therapies in cognitively healthy people who are at higher risk of developing a build-up in the brain of amyloid protein.
The science fraternity across the globe is working rigorously on finding a possible indicator of Alzheimer’s. Presently, Alzheimer’s can only be detected in the later stage of its development when significant brain damage has already occurred. Clinically, it is detected with the help of Beta-amyloid protein, a toxic protein found in the sticky brain.
Immunotherapy, which is in Phase II clinical trials, is the first experiment of Novartis. It is an injectable medicine which stimulates the immune system to produce natural antibodies that attack the toxic amyloid proteins.
BACE inhibitor drug, an oral pill which is about to enter Phase I trials, is the second treatment.
Both the treatments work by blocking beta secretase enzyme that is involved in production of beta-amyloid.
The clinical trial will involve over 1,300 cognitively healthy patients who are in the age group 60 and 75 and do not have symptoms of dementia.
Facts and Figures
The medical science seems to be making progress in finding successful treatment for Alzheimer’s disease. Recently, a blood test was developed by the scientists to predict the onset of Alzheimer’s. Now, an Indian-origin scientist has claimed that our eyes and sense of smell can predict the onset of disease, and that too in a cheaper and easier way.
According to the Alzheimer’s Disease Facts and Figures report, the disease is the sixth leading killer in our country.
According to Alzheimer’s Association, the number of Americans with Alzheimer’s disease and other types of dementia will grow as the US population of those age 65 and older increases.
Dementia has affected 44 million people across the globe and the figures are set to zoom to 135 million by 2050, according to a non-profit campaign group Alzheimer’s Disease International. In 2014, it’s expected that USD 214 billion will be spent on people suffering from the disease or a form of it.
Alzheimer’s affects patient’s memory, communication skills and their executive functions. Moreover, it is the most common form of dementia and the sixth leading cause of death for older Americans, according to the Centers for Disease .
Latest posts by Christina Langfold (see all)
- Grass Carps Are Invading The Waters Of 3 Great Lakes - Jan 31, 2017
- Michael Lynton Will Be The New Snap Chairman - Jan 15, 2017
- US Hospitals Penalized For High Rates Of Patient Injuries - Dec 26, 2016